文档介绍：中国药物警戒 第 19 卷第 4 期 2022 年 4 月 April, 2022, ,
（ Results
People's Republic of China (2020 edition) ChP). Among the two hundred and three specifications of CPM, only
one mentioned the incompatibility of drugs and seven presented antagonistic ingredients. The package inserts of twenty-
three specifications mentioned syndrome type contraindications, five of which were inconsistent with the ChP. Fifty-
seven specifications contained pregnancy contraindication labels, which were inconsistent with the ChP in five cases.
In addition, there were twenty-two specifications that contained diet taboos, thirteen of which differed from those of the
Conclusion
ChP. Some package inserts of CPM have substandard labels of contraindications that show poor consistency
with the ChP. Drug regulatory departments should continue to strengthen supervision and management. Meanwhile, it is
necessary to enhance the quality of prescriptions and to improve the contents of the (ChP).
Keywords:
Chinese patent medicine; package inserts; contraindications; Pharmacopoeia of the People's Republic of China
中药用药禁忌是指在使用中药时，为确保临床疗 致的中成药不良反应报道逐渐增多 [3-5]，患